- Home
- MANE vs LEGN Comparison
MANE vs LEGN Comparison
Compare MANE & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MANE | LEGN |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.7B |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MANE | LEGN |
|---|---|---|
| Price | $139.63 | $21.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 13 |
| Target Price | ★ $170.50 | $45.62 |
| AVG Volume (30 Days) | 784.2K | ★ 1.9M |
| Earning Date | 11-10-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $39.73 |
| Revenue Next Year | N/A | $23.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.43 | $16.24 |
| 52 Week High | $146.58 | $37.50 |
Technical Indicators
Market Signals| Indicator | MANE | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 61.55 | 60.31 |
| Support Level | $92.62 | $17.08 |
| Resistance Level | N/A | $21.99 |
| Average True Range (ATR) | 7.62 | 1.17 |
| MACD | 1.38 | 0.42 |
| Stochastic Oscillator | 80.00 | 71.77 |
Price Performance
Historical ComparisonAbout MANE Veradermics Incorporated Common Stock
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.